Last reviewed · How we verify

Clinical-judged midazolam administration

Chang Gung Memorial Hospital · FDA-approved active Small molecule

Clinical-judged midazolam administration is a Benzodiazepine Small molecule drug developed by Chang Gung Memorial Hospital. It is currently FDA-approved for Procedural sedation and anxiolysis, Preoperative anxiolysis, Induction of general anesthesia.

Midazolam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to produce sedation, anxiolysis, and amnesia.

Midazolam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to produce sedation, anxiolysis, and amnesia. Used for Procedural sedation and anxiolysis, Preoperative anxiolysis, Induction of general anesthesia.

At a glance

Generic nameClinical-judged midazolam administration
SponsorChang Gung Memorial Hospital
Drug classBenzodiazepine
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia/Sedation
PhaseFDA-approved

Mechanism of action

Midazolam binds to benzodiazepine receptors on GABA-A channels, increasing chloride ion influx and hyperpolarizing neuronal membranes. This potentiates the inhibitory effects of GABA, resulting in dose-dependent central nervous system depression. Clinical-judged administration refers to individualized dosing based on patient response and clinical assessment rather than fixed protocols.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Clinical-judged midazolam administration

What is Clinical-judged midazolam administration?

Clinical-judged midazolam administration is a Benzodiazepine drug developed by Chang Gung Memorial Hospital, indicated for Procedural sedation and anxiolysis, Preoperative anxiolysis, Induction of general anesthesia.

How does Clinical-judged midazolam administration work?

Midazolam is a benzodiazepine that enhances inhibitory GABAergic neurotransmission in the central nervous system to produce sedation, anxiolysis, and amnesia.

What is Clinical-judged midazolam administration used for?

Clinical-judged midazolam administration is indicated for Procedural sedation and anxiolysis, Preoperative anxiolysis, Induction of general anesthesia, Acute agitation and anxiety.

Who makes Clinical-judged midazolam administration?

Clinical-judged midazolam administration is developed and marketed by Chang Gung Memorial Hospital (see full Chang Gung Memorial Hospital pipeline at /company/chang-gung-memorial-hospital).

What drug class is Clinical-judged midazolam administration in?

Clinical-judged midazolam administration belongs to the Benzodiazepine class. See all Benzodiazepine drugs at /class/benzodiazepine.

What development phase is Clinical-judged midazolam administration in?

Clinical-judged midazolam administration is FDA-approved (marketed).

What are the side effects of Clinical-judged midazolam administration?

Common side effects of Clinical-judged midazolam administration include Respiratory depression, Hypotension, Oversedation, Paradoxical reaction (agitation), Amnesia.

What does Clinical-judged midazolam administration target?

Clinical-judged midazolam administration targets GABA-A receptor and is a Benzodiazepine.

Related